Core Insights - AbbVie is showcasing significant advancements in its oncology portfolio at the upcoming ASCO Annual Meeting, highlighting investigational antibody-drug conjugates (ADCs) targeting various difficult-to-treat cancers [2][3]. Group 1: Key Data Presentations - The investigational ADC telisotuzumab adizutecan (ABBV-400, Temab-A) demonstrated a 63% objective response rate (ORR) in a Phase 1 study involving 41 patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) [3][4]. - ABBV-706, another ADC targeting high-grade neuroendocrine neoplasms (NENs), showed a 31.3% ORR in a Phase 1 study with a median duration of response (DoR) of 5.6 months [4]. - Pivekimab sunirine (PVEK) achieved a 70% composite complete response (CCR) rate in untreated patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA trial [4][5]. Group 2: Ongoing Clinical Trials - Telisotuzumab adizutecan is being evaluated in multiple ongoing trials, including a Phase 1/2 study in first-line NSCLC and a Phase 3 study in refractory metastatic colorectal cancer [3]. - ABBV-706 is under investigation as monotherapy and in combination with other therapies for advanced solid tumors expressing SEZ6 [4]. - Pivekimab sunirine is also being studied in a Phase 1/2 trial for relapsed/refractory acute myeloid leukemia [5]. Group 3: Company Commitment and Strategy - AbbVie emphasizes its commitment to transforming cancer care through targeted therapies and biomarker-driven approaches, reflecting a significant expansion of its ADC portfolio [6][14]. - The company is advancing over 35 investigational medicines across various cancer types, aiming to address unmet medical needs in oncology [15].

Core Insights - Legend Biotech Corporation is presenting new data on CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma at the 2025 ASCO and EHA meetings, highlighting its status as a market leader in CAR-T therapy for this condition [1][2] - The company is also showcasing preliminary results from ongoing Phase 1 studies targeting solid tumors, specifically lung and gastric cancers, indicating an expansion of its cell therapy pipeline [1][2] CARVYKTI Data - Long-term data from the CARTITUDE-1 study will be presented, showing that heavily pretreated patients with relapsed or refractory multiple myeloma achieved a median progression-free survival of over 5 years after a single CARVYKTI infusion, with a median follow-up of 60.3 months [3][10] - Data from the CARTITUDE-4 study will support a positive benefit-risk ratio for CARVYKTI across various patient subgroups, including those with high-risk cytogenetics [4][10] Solid Tumor Pipeline - Preliminary results from Phase 1 studies of LB2102 and LB1908, targeting small-cell lung cancer and gastroesophageal adenocarcinoma respectively, will be featured in poster presentations at ASCO [6][10] - LB2102 has been licensed to Novartis for further development, with Legend Biotech responsible for the Phase 1 clinical trial in the U.S. [7][8] Clinical Presentations - The company will present data at ASCO and EHA, including an oral presentation on long-term survival outcomes for CARVYKTI and poster presentations on subgroup analyses and preliminary results from solid tumor studies [10][12]